Human immunodeficiency virus infection, Part II

Disease-a-Month

Volumn 44, Issue 12, 1998, Pages 677-716

  Horowitz, Harold W ^a,b   Telzak, Edward E ^c,d   Sepkowitz, Kent A ^e   Wormser, Gary P ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c BRONX LEBANON HOSPITAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MYCOBACTERIUM AVIUM; PNEUMOCYSTIS PNEUMONIA; REVIEW;

EID: 84866230644     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(98)90013-x     Document Type: Review

References (45)

1. Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46(No. RR-12):1-46.
2. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-31.
3. Phair JP, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
4. Crowe SM, Carlin JB, Stewart KI, Lucas R, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:770-6.
5. Hay JW, Osmond DH, Jacobson MA. Protecting the medical costs of AIDS and ARC in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;1:466-85.
6. Hirschel B, Lazzarin A, Chopard P, et al. A controlled trial for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-83.
7. Montaner JSG, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled trial. Ann Intern Med 1991;114:948-53.
8. Leoung GS, Feigal DW Jr, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco Community Prophylaxis Trial. N Engl J Med 1990;323:769-75.
9. Ruskin J, LaRiviere M. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991;337:468-71.
10. Wormser GP, Horowitz HW, Duncanson FP, et al. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Arch Intern Med 1991;151:688-92.
11. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
12. Bozzette SA, Forthal D, Sattler FR, et al. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. Am J Med 1995;98:177-82.
13. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992;327:1842-8.
14. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995;122:755-61.
15. Antinori A, Murri R, Ammassari A, et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995;9:1343-50.
16. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole for prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;17:106-11.
17. Gordin F, Simon G, Wofsy C, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
18. El-Sadr W, Murphy R, Luskin-Hawk R, et al. Atovaquone (ATV) versus dapsone (DAP) in the prevention of p. carinii pneumonia (PCP) in patients intolerant to trimethoprim and/or sulfamethoxazole (TMP/SMX) CPCRA 034/ACTG 277. In: Proceedings of the 35th Annual Meeting of the Infectious Diseases Society of America; 1997 Sept 13-16; San Francisco, California. Abstract 769.
19. Havlir DV, Dube MP, Sattler FR. et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin. or both. N Engl J Med 1996;335:392-8.
20. Girard P-M, Landman R, Gaudebout C. et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993;328:1514-20.
21. Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant. HIV- infected individuals. AIDS 1993;7:355-9.
22. Gelber RH. Rees RJW. Dapsone metabolism in patients with dapsone-resistant leprosy. Am J Trop Med Hyg 1975;24:963-7.
23. Casale L, Gold H. Schechter C. Naficy A. Masci JR. Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency. Chest 1993;103:342-4.
24. Saah AJ, Hoover DR, Peng Y. et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA 1995;273:1197-202.
25. Karboski JA. Godley PJ. Inhaled pentamidine and hypoglycemia. Ann Intern Med 1988;108:490.
26. Herer B, Chinet T, Labrune L, et al. Pancreatitis associated with pentamidine by aerosol. BMJ 1989;298:695.
27. Hart CC. Aerosolized pentamidine and pancreatitis. Ann Intern Med 1989;111:691.
28. Kronawitter U. Bogner JR. Goebel FD. Low incidence of Pneumocystis pneumonia in HIV patients receiving 300 mg pentamidine aerosol every 2 weeks. Clin Invest Med 1992;70:1089-91.
29. Ena J. Amador C. Pasquau F. et al. Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1994;18:901-4.
30. Anonymous. Atovaquone for Pneumocystis carinii pneumonia. Med Lett Drugs Ther 1993;35:28-9.
31. Comley JC. Sterling AM. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. Antimicrob Agents Chemother 1995;39:806-11.
32. Bachmeyer C. Salmon D, Guerin C. et al. Trimethoprim-sulphamethoxazole desensitization in HIV-infected patients: an open study. AIDS 1995;9:299-312.
33. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995;20:849-53.
34. Piketty C, Gilquin J, Kazatchkine MD. Efficacy and safety of desensitization to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. J Infect Dis 1995;172:611.
35. Nguyen M-T, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1995;9:573-5.
36. Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994;93:1001-5.
37. Abel AG, Nierman DM, Ilowite JS, et al. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis. Chest 1988;94:329-31.
38. Scannell KA. Atypical presentation of Pneumocystis carinii pneumonia in patients receiving inhalational pentamidine. Am J Med 1988;85:881-4.
39. Jules-Elysee K, Stover D, Zaman M, et al. Aerosolized pentamidine: effect on the diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 1990;112:750-7.
40. Grant IH, Gold JWMj, Rosenblum M, Niedzwiecki D, Armstrong D. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 1990;4:519-21.
41. Zangerle R, Allerberger F. High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:207-8.
42. Oksenhendler E, Charreau I, Tournerie C, Azihary M, Carbon C, Aboulker J-P. Toxoplasma gondii infection in advanced HIV infection. AIDS 1994;8:843-7.
43. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. Aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995;20:531-41.
44. Clotet B, Si G, Romeu J, et al. Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS 1991;5:601-2.
45. Jacobson MA, Besch CL, Child C, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. J Infect Dis 1994;169:384-94.